We’re used to seeing biotech stocks surge because of the results of a clinical trial… but it’s quite crazy to see the whole market pinning its hopes on a clinical trial. Gilead’s (GILD) Remdisivir had some weak results leak last week and that helped inspire the market selloff (“Oh no, we won’t get a drug […]
Articles
It’s not uncommon to see these pitches that are based on daydreams of, “What if you had bought Brand Name Stock X 50 years ago?” And there’s a reason for that: They’re compelling, they help you to think about long time horizons, and they play off of a huge bias that we all have to […]
Lots of readers have been sending questions our way about Porter Stansberry’s new high-cost Stansberry Venture Value newsletter, which is his attempt to build a service that essentially recommends small cap value stocks for long-term compounding value. An admirable goal, and I guess we’ll start to learn in the coming year or two how it’s […]
Today’s teaser happens to also concern a stock that I’ve been curious about, so I’m taking the opportunity to follow the hints down the rabbit hole and do a little chewing on whatever it is I find down there. The teaser ad comes in from Motley Fool Canada in an ad for their Stock Advisor […]
The Zed Files[Ed. Note: Dr. KSS writes for the Irregulars about medicine and biotech stocks. He has agreed to our trading restrictions, chooses his own topics, and his words and opinions are his own. Enjoy!] It could be the premise of a tawdry unrated movie that teenage boys sneak glimpses of on Netflix when they’re home alone. […]
That “top stock” headline is the promise of Ian Wyatt, not myself, just to be clear. Wyatt and Taylor Laundon put out a letter called Top Stock Insights, the text of the ad for that letter says it’s from Taylor and the letter is “signed” by Ian Wyatt, so I guess we’ll assume it’s a […]
The latest screed from Danielle O’Dell for the Money Map Report is aimed at first getting you all fired up about Obamacare, in case you’re one of the seven people in the United States that doesn’t already have a strong opinion about that law’s impending enactment, and then, more importantly, at telling you that she’s […]
I do have a quick teaser unveiling to share with you for today’s Friday File, but I want to start with a look at a stock that I own and that I suggested to the Irregulars several years ago, Sprott Resource Corp. (SCP in Canada, SCPZF on the pink sheets) Why? Because they just agreed […]
Yiannis Mostrous teased us well over a year ago about the stock that he thought was “the next McDonald’s” … and readers are telling me that he’s sending out a very similar ad campaign right now, so I thought I’d take a look. At the time, Mostrous was looking for subscribers to his Silk Road […]
Tom Dyson edits the 12% Letter — a newsletter that, you will probably be unsurprised to hear, aims to recommend investments that provide high income using dividends (and other strategies). His publisher has been pushing out an ad lately that touts their “dividend capture” strategy, which I don’t have the heart to describe yet again […]
There’s a new teaser going around from a Stansberry newsletter, this time it’s from the 12% Letter by Tom Dyson, and it’s teasing us about a secret retirement plan they call the 801K. They’ve got a special report to send you called How to build a $1,000,000 Retirement with “U.S. 801(k) Plans” … and all […]
Comments
That ad has been running for a long time now, but it's Editas... covered here most recently: https://www.stockgumshoe...
Speaking of cancer treatments..................................................... "One drop of company’s breakthro...
Looking @ your progress spreadsheet, to be fair to Dylan Jovine, he recommended RSH last fall when it was around $16-$17...